Welcome to our dedicated page for Teva Pharm SEC filings (Ticker: TEVA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
The Teva Pharmaceutical Industries Limited (TEVA) SEC filings page on Stock Titan provides access to the company’s U.S. regulatory disclosures, including current reports on Form 8‑K and other key documents filed with the Securities and Exchange Commission. As an issuer with American Depositary Shares listed on the New York Stock Exchange under the symbol TEVA, Teva reports material events, financing arrangements and financial results through these filings.
Recent Form 8‑K filings include items on results of operations and financial condition, where Teva furnishes press releases announcing quarterly financial results for periods such as the quarters ended June 30 and September 30. These filings typically incorporate earnings press releases by reference and clarify that the information is being furnished rather than filed for purposes of the Exchange Act. Another 8‑K describes Teva’s presentation at a major healthcare conference and includes expectations regarding performance for the 2025 fiscal year.
Teva also uses Form 8‑K to disclose material definitive agreements and related direct financial obligations. For example, an 8‑K details the Third Amendment to the Senior Unsecured Sustainability-Linked Revolving Credit Agreement, which extended the maturity date of the revolving facility and amended financial covenants such as the maximum leverage ratio and conditions tied to investment grade status. These filings provide insight into Teva’s capital structure, liquidity management and covenant framework.
On Stock Titan, investors can review these filings alongside AI-powered summaries that explain the main points of each document in plain language. This includes highlighting key terms in credit agreements, summarizing earnings-related disclosures, and pointing out items that may affect leverage, liquidity or future reporting. Users interested in TEVA can use the filings page to track quarterly and annual reporting, current reports on material events, and disclosures related to financing arrangements, while AI tools help interpret lengthy or technical sections of the filings.
TEVA Pharmaceuticals filed a Form 144 reporting the planned sale of 447,778 ordinary shares. The filing lists Citigroup Global Markets Inc. as the broker and shows the transaction date 02/17/2026 on the NYSE. The filing also lists restricted share unit and performance share unit award amounts of 161,656 and 620,110 respectively, both with an award date of 02/15/2023.
Migdal Insurance & Financial Holdings Ltd. filed a Schedule 13G reporting beneficial ownership of 61,689,363 Teva Pharmaceutical Industries Ltd. ordinary shares, representing 5.37% of the class, based on 1,149,812,898 shares outstanding as of December 31, 2025.
The shares are held through various Migdal subsidiaries that manage insurance, pension, provident, mutual fund and portfolio accounts, each under independent management. As of January 20, 2026, the filing lists 107,000 shares held by Migdal Insurance Company Ltd., 53,935,231 shares by Migdal Sal Domestic Equities, and 7,647,132 shares by Migdal Mutual Funds Ltd.
The filing emphasizes that these securities are not held to change or influence control of Teva and that Migdal and its subsidiaries disclaim beneficial ownership beyond their actual economic interest.
Harel Insurance Investments & Financial Services Ltd filed an amended Schedule 13G reporting beneficial ownership of 72,325,555 Teva Pharmaceutical Industries Ltd ordinary shares, representing 6.3% of the class based on 1,149,812,898 shares outstanding as of December 31, 2025.
Harel explains that 70,039,163 shares are held for public investors through various funds and insurance products managed by its subsidiaries, 1,090,246 shares are held in third-party client accounts, and 1,196,146 shares are held for its own account. Harel disclaims beneficial ownership of more than the 1,196,146 shares held for its own account.
The filing shows Harel has no sole voting or dispositive power, with shared voting power over 71,235,309 shares and shared dispositive power over 72,325,555 shares. Harel certifies the holdings are not for the purpose of changing or influencing control of Teva.
Teva Pharmaceutical Industries files its Annual Report on Form 10-K, outlining a global biopharmaceutical business built on generics, biosimilars and innovative medicines across three segments: United States, Europe and International Markets.
The company highlights key branded CNS products such as AUSTEDO, AJOVY, UZEDY and COPAXONE, plus oncology and respiratory franchises, while expanding a broad biosimilars portfolio through collaborations with Samsung Bioepis, Formycon, Prestige Biopharma and others. Teva reports a 2025 workforce of 33,950 employees in 57 countries and 1,149,812,898 ordinary shares outstanding as of December 31, 2025.
Management emphasizes its “Pivot to Growth” strategy, including focus on high-value and complex generics, divestiture of the API business, AI-driven efficiency initiatives, and continued network optimization. The filing also details extensive U.S., European and international regulatory frameworks, including the Inflation Reduction Act’s impact on AUSTEDO Medicare pricing from 2027 and Teva’s ongoing legal challenge to aspects of the program.
Teva Pharmaceutical Industries executive Eliyahu Sharon Kalif, EVP and Chief Financial Officer, received 141,478 restricted share units on January 27, 2026. These units were granted at a price of $0.00 per unit.
Each restricted share unit represents a contingent right to receive, at settlement, one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. The units were issued after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. The ordinary shares may be represented by American Depositary Shares, each currently representing one ordinary share.
Teva Pharmaceutical Industries executive Eric A. Hughes, Executive Vice President, Global R&D and Chief Medical Officer, received 141,478 restricted share unitsJanuary 27, 2026. Each unit represents a right to receive one ordinary share or, at the committee’s option, the cash value of one share.
The restricted share units were earned after performance criteria were met and remain subject to time-based vesting, scheduled to vest on March 3, 2026. Following this award, Hughes directly beneficially owned 141,478 derivative securities tied to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. executive Mark Sabag reported an equity award of 141,478 restricted share units effective January 27, 2026. Each unit represents a contingent right to receive one ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share.
The restricted share units were received upon satisfaction of performance criteria tied to performance share units and remain subject to time-based vesting. These units are scheduled to vest on March 3, 2026. Following this award, Sabag directly beneficially owned 141,478 derivative securities linked to Teva ordinary shares.
Teva Pharmaceutical Industries Ltd. reported that Exec. VP, European Commercial, Richard Daniell was granted 141,478 restricted share units (RSUs) on January 27, 2026. Each RSU represents a right to receive one ordinary share or, at the committee’s option, the cash value of one ordinary share.
The RSUs were earned upon satisfaction of performance criteria tied to earlier performance share units and remain subject to time-based vesting. They are scheduled to vest on March 3, 2026. The underlying ordinary shares may be represented by American Depositary Shares, with each ADS currently equal to one ordinary share.
Teva Pharmaceutical Industries’ President and CEO Richard D. Francis received new equity-based awards in the form of restricted share units (RSUs). On January 27, 2026, he was granted 620,110 RSUs that were earned after meeting performance criteria and will continue to vest on February 15, 2026. He was also granted an additional 891,315 RSUs that were earned upon satisfaction of separate performance goals and will vest on March 3, 2026.
Each RSU represents a contingent right to receive either one Teva ordinary share or, at the Human Resources and Compensation Committee’s option, the cash value of one ordinary share. These awards are held directly by Francis and compensate performance while tying a significant portion of his compensation to Teva’s equity.
Teva Pharmaceutical Industries Limited furnished an update on its business performance by submitting an 8-K tied to its latest earnings release. On January 28, 2026, the company issued a press release detailing financial results for the period ended December 31, 2025, covering both full-year 2025 and fourth quarter performance. This press release is provided as Exhibit 99.1 and is incorporated by reference into the report, but the underlying financial figures and metrics appear only in the exhibit itself. The 8-K specifies that this earnings information is being furnished rather than filed, which affects how it is treated under U.S. securities laws.